amoxicillin as amoxicillin trihydrate 875 MG clavulanic acid as clavulanate potassium 125 MG Oral Tablet
INDICATIONS AND USAGE Amoxicillin and Clavulanate Potassium Tablets are indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower Respiratory Tract Infections – caused by β-lactamase-producing strains of H. influenzae and M. catarrhalis . Otitis Media – caused by β-lactamase-producing strains of H. influenzae and M. catarrhalis . Sinusitis – caused by β-lactamase-producing strains of H. influenzae and M. catarrhalis . Skin and Skin Structure Infections – caused by β-lactamase-producing strains of S. aureus , E. coli, and Klebsiella spp. Urinary Tract Infections – caused by β-lactamase-producing strains of E. coli , Klebsiella spp., and Enterobacter spp. While Amoxicillin and Clavulanate Potassium Tablets are indicated only for the conditions listed above, infections caused by ampicillin-susceptible organisms are also amenable to treatment with Amoxicillin and Clavulanate Potassium Tablets due to its amoxicillin content; therefore, mixed infections caused by ampicillin-susceptible organisms and β-lactamase-producing organisms susceptible to Amoxicillin and Clavulanate Potassium Tablets should not require the addition of another antibiotic. Because amoxicillin has greater in vitro activity against S. pneumoniae than does ampicillin or penicillin, the majority of S. pneumoniae strains with intermediate susceptibility to ampicillin or penicillin are fully susceptible to amoxicillin and Amoxicillin and Clavulanate Potassium Tablets. (See Microbiology .) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Amoxicillin and Clavulanate Potassium Tablets and other antibacterial drugs, Amoxicillin and Clavulanate Potassium Tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Bacteriological studies, to determine the causative organisms and their susceptibility to Amoxicillin and Clavulanate Potassium Tablets, should be performed together with any indicated surgical procedures.
Lake Erie Medical & Surgical Supply DBA Q
OVAL WHITE GGN7
Related Pills
amoxicillin as amoxicillin trihydrate 875 MG clavulanic acid as clavulanate potassium 125 MG Oral Tablet
Lake Erie Medical & Surgical Supply DBA Q
DISCLAIMER:
"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."
"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."
"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."
PillSync may earn a commission via links on our site
HOW SUPPLIED Amoxicillin and Clavulanate Potassium Tablets, USP, 500 mg/125 mg: Each film coated tablet, for oral administration, is white, oval-shaped, debossed GGN6 on one side and plain on the reverse side, and contains 500 mg amoxicillin as the trihydrate and 125 mg clavulanic acid as the potassium salt. NDC 54868-4743-2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . bottles of 15 NDC 54868-4743-0 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . bottles of 20 NDC 54868-4743-1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . bottles of 30 Amoxicillin and Clavulanate Potassium Tablets, USP, 875 mg/125 mg: Each film coated tablet, for oral administration, is white, capsule-shaped, scored and debossed GGN7 on one side and scored on the reverse side, and contains 875 mg amoxicillin as the trihydrate and 125 mg clavulanic acid as the potassium salt. NDC 54868-4951-0 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . bottles of 10 NDC 54868-4951-2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . bottles of 14 NDC 54868-4951-1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . bottles of 20 NDC 54868-4951-4 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . bottles of 28 NDC 54868-4951-3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . bottles of 30 Store at 20°-25 °C (68°-77°F) [See USP Controlled Room Temperature]. Dispense in tightly closed, moisture-proof containers.
More pills like OVAL GGN7